Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $66.94M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.61M
Average 0.60M
ACRV Total Non-current Liabilities
All obligations due after more than one year.
Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 47.6% from a year ago
Total non-current liabilities stood at $1.26M at the end of Q1 FY2026, down 47.6% from a year earlier and down 17.8% from the prior quarter. Over 3 fiscal years it compounded at -28.7% a year.
Context
- Total non-current liabilities amounted to 1.2% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -47.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.54M USD
- Year-over-year change
- -40.6%
- 4-year CAGR
- -66.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.54M | -40.6% |
| FY2024 | 2024-12-31 | 2.59M | -31.3% |
| FY2023 | 2023-12-31 | 3.77M | -11.1% |
| FY2022 | 2022-12-31 | 4.24M | -96.7% |
| FY2021 | 2021-12-31 | 127.48M | — |
Total Non-current Liabilities vs competitors
How ACRV compares with its peers on the latest reported figures
- ACRV's Mar 2026 total non-current liabilities of $1.26M is the 7th highest of the 10 companies compared; the peer median is $9.1M.
- Its year-over-year change of -47.6% is the 8th highest of 9, against a peer median of -10.4%.
- Total non-current liabilities amounts to 1.2% of total assets for ACRV, versus a peer median of 5.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $274.78M | +14.5% | +170.0% | 84.8% |
| Mar 2026 | $85.1M | -8.2% | +1.8% | 42.1% | |
| Mar 2026 | $18.37M | +182.6% | +120.7% | 39.6% | |
| Mar 2026 | $10.21M | -12.7% | +3.3% | 12.8% | |
| Mar 2026 | $9.1M | -37.0% | -23.1% | 5.1% | |
| Mar 2026 | $3.74M | +49714.6% | — | 1.6% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.26M | -47.6% | -28.7% | 1.2% |
| Mar 2026 | $217K | — | — | 0.3% | |
| Mar 2026 | $146K | -30.5% | -52.4% | 0.1% | |
| Mar 2026 | $0 | -100.0% | -68.1% | 0.0% | |
| Peer median (excluding ACRV) | $9.1M | -10.4% | +1.8% | 5.1% | |
Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99.6M | 29.52M | 36.02M | 39.82M | 41.5M |
| Short-term Investments | 0 | 98.23M | 91.44M | 139.66M | 77.08M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.34M | 2.23M | 2.15M | 1.86M |
| Total Current Assets | 100.41M | 132.1M | 129.69M | 181.63M | 120.45M |
| Property, Plant & Equipment (Net) | 5.79M | 6.86M | 7.91M | 8.03M | 7.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 41.88M | 0 | 5.09M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 388K | 388K | 665K | 1.85M | 1.86M |
| Total Non-current Assets | 6.18M | 49.13M | 8.57M | 14.96M | 9.27M |
| Total Assets | 106.59M | 181.23M | 138.27M | 196.59M | 129.72M |
| Account Payables | 964K | 904K | 5.05M | 758K | 2.28M |
| Short-term Debt | 0 | 0 | 0 | 1.06M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 66K | 69K | 0 | 0 | 0 |
| Other Current Liabilities | 667K | 2.66M | 3.86M | 5.46M | 5.56M |
| Total Current Liabilities | 2.91M | 6.52M | 13.3M | 17.21M | 15.66M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 122.52M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 127.48M | 4.24M | 3.77M | 2.59M | 1.54M |
| Total Liabilities | 130.4M | 10.75M | 17.07M | 19.8M | 17.2M |
| Common Stock | 2K | 22K | 23K | 31K | 31K |
| Retained Earnings | (24.87M) | (56.03M) | (116.42M) | (196.98M) | (274.88M) |
| Accumulated OCI | 0 | (95K) | (83K) | 447K | 111K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.81M) | 170.48M | 121.2M | 176.79M | 112.52M |
| Total Debt | 5.63M | 4.96M | 4.64M | 3.65M | 2.71M |
| Net Debt | (93.98M) | (24.56M) | (31.37M) | (36.17M) | (38.79M) |
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.